Abiopharma

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

IQM、バンガード取締役でデロイト デジタル元グローバル責任者のバーバラ・ヴェネマンを取締役に任命

IQM任命Vanguard董事、前Deloitte Digital全球负责人Barbara Venneman为董事会成员

IQM任命Vanguard董事、前Deloitte Digital全球負責人Barbara Venneman為董事會成員

IQM beruft Barbara Venneman, Vorstandsmitglied bei Vanguard und ehemalige Global Head von Deloitte Digital, in seinen Vorstand

IQM nomina Barbara Venneman, Direttore del CdA di Vanguard ed ex Responsabile globale di Deloitte Digital, al suo consiglio di amministrazione

Identifying Details of New Security-ICL B8-I

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

Bitmine Immersion Technologies gibt erste Dividendenausschüttung und Notierung der Vorzugsaktien der Serie A an der NYSE bekannt